432 related articles for article (PubMed ID: 22945689)
1. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia.
Lech-Maranda E; Mlynarski W; Grzybowska-Izydorczyk O; Borowiec M; Pastorczak A; Cebula-Obrzut B; Klimkiewicz-Wojciechowska G; Wcislo M; Majewski M; Kotkowska A; Robak T; Warzocha K
Genes Chromosomes Cancer; 2013 Mar; 52(3):287-96. PubMed ID: 23225254
[TBL] [Abstract][Full Text] [Related]
3. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
4. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
[TBL] [Abstract][Full Text] [Related]
5. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
[TBL] [Abstract][Full Text] [Related]
6. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
7. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
[TBL] [Abstract][Full Text] [Related]
8. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors.
Visco C; Maura F; Tuana G; Agnelli L; Lionetti M; Fabris S; Novella E; Giaretta I; Reda G; Barcellini W; Baldini L; Neri A; Rodeghiero F; Cortelezzi A
Clin Cancer Res; 2012 Apr; 18(7):1870-8. PubMed ID: 22322667
[TBL] [Abstract][Full Text] [Related]
9. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.
Morabito F; Cutrona G; Gentile M; Matis S; Todoerti K; Colombo M; Sonaglio C; Fabris S; Reverberi D; Megna M; Spriano M; Lucia E; Rossi E; Callea V; Mazzone C; Festini G; Zupo S; Molica S; Neri A; Ferrarini M
Br J Haematol; 2009 Jun; 146(1):44-53. PubMed ID: 19438486
[TBL] [Abstract][Full Text] [Related]
10. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
[TBL] [Abstract][Full Text] [Related]
11. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
12. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
[TBL] [Abstract][Full Text] [Related]
13. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
14. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
[TBL] [Abstract][Full Text] [Related]
15. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
16. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
17. [Overrepresentation of specific gene segments of expressed immunoglobulin heavy chain variable region among unmutated and mutated patients with chronic lymphocytic leukemia].
Yu Z; Li ZJ; Yi SH; Zhou KS; Hao M; Qi JY; Li CH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):529-32. PubMed ID: 22338175
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
19. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.
Francis S; Karanth M; Pratt G; Starczynski J; Hooper L; Fegan C; Pepper C; Valcarcel D; Milligan DW; Delgado J
Cancer; 2006 Sep; 107(5):1023-33. PubMed ID: 16862572
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
